- Home
- BWB vs TERN Comparison
BWB vs TERN Comparison
Compare BWB & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- TERN
- Stock Information
- Founded
- BWB 2005
- TERN 2017
- Country
- BWB United States
- TERN United States
- Employees
- BWB N/A
- TERN N/A
- Industry
- BWB Major Banks
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- TERN Health Care
- Exchange
- BWB Nasdaq
- TERN Nasdaq
- Market Cap
- BWB 365.0M
- TERN 355.9M
- IPO Year
- BWB 2018
- TERN 2021
- Fundamental
- Price
- BWB $13.72
- TERN $3.45
- Analyst Decision
- BWB Strong Buy
- TERN Buy
- Analyst Count
- BWB 2
- TERN 6
- Target Price
- BWB $17.50
- TERN $18.30
- AVG Volume (30 Days)
- BWB 47.3K
- TERN 1.0M
- Earning Date
- BWB 04-23-2025
- TERN 05-12-2025
- Dividend Yield
- BWB N/A
- TERN N/A
- EPS Growth
- BWB N/A
- TERN N/A
- EPS
- BWB 1.03
- TERN N/A
- Revenue
- BWB $106,036,000.00
- TERN N/A
- Revenue This Year
- BWB $26.46
- TERN N/A
- Revenue Next Year
- BWB $12.13
- TERN N/A
- P/E Ratio
- BWB $13.48
- TERN N/A
- Revenue Growth
- BWB N/A
- TERN N/A
- 52 Week Low
- BWB $10.52
- TERN $3.24
- 52 Week High
- BWB $16.00
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- BWB 42.87
- TERN 36.30
- Support Level
- BWB $13.60
- TERN $3.24
- Resistance Level
- BWB $14.19
- TERN $3.68
- Average True Range (ATR)
- BWB 0.36
- TERN 0.24
- MACD
- BWB -0.07
- TERN 0.02
- Stochastic Oscillator
- BWB 17.47
- TERN 26.92
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc offers retail and commercial loan and deposit services to customers within the Minneapolis-St. Paul-Bloomington, MN-WI Metropolitan Statistical Area. The company engages in providing a wide range of deposit and lending products. Its products and services include commercial deposits, loans, online business services, credit card, mobile banking, and remote deposit services.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.